Effect of direct oral anticoagulants in cirrhosis: an in vitro study
The anticoagulant potency of DOAC differs according to the individual procoagulant potential. Highly procoagulant plasma from patients with cirrhosis is less sensitive to the anticoagulant action of apixaban, edoxaban, and rivaroxaban than control plasma. These results, if confirmed in vivo, would support the concept of personalizing anticoagulant treatment in patients with a highly procoagulant state.
Authors
- Lucas Veuthey (ORCID: https://orcid.org/0000-0003-3556-0430)
- Lorenzo Alberio (ORCID: https://orcid.org/0000-0001-9686-9920)
- Cindy Pereira Portela (ORCID: https://orcid.org/0000-0002-5348-8498)
- Maxime Grégoire Zermatten (ORCID: https://orcid.org/0000-0002-9298-8268)
- Alessandro Aliotta (ORCID: https://orcid.org/0000-0002-9382-138X)
- Debora Bertaggia Calderara (ORCID: https://orcid.org/0000-0002-9756-4974)
- Darius Moradpour (ORCID: https://orcid.org/0000-0003-1977-6792)
- Elise Mdawar-Bailly (ORCID: https://orcid.org/0009-0005-7049-7045)
- Montserrat Fraga (ORCID: https://orcid.org/0000-0001-9408-3094)
- Lucas A. Gautier
Institutions
- Centre Hospitalier Universitaire Vaudois (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- Journal of Thrombosis and Haemostasis
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.jtha.2025.03.011
- Citations
- 4
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Centre Hospitalier Universitaire Vaudois